Eli Lilly wins over Noom GLP-1 dose claims

On 26 May 2026 the National Advertising Division (NAD), the self-regulatory advertising body run by BBB National Programs, recommended that Noom change or drop its "A Smaller Dose. A Smarter Start" tagline for the company's Microdose GLP-1Rx Program^[1]. The challenge was filed by Eli Lilly, maker of the GLP-1 receptor agonist tirzepatide (sold as Mounjaro for type 2 diabetes and as Zepbound for weight management in the US).

NAD found that Noom had not provided adequate evidence that its lower-dose approach offers a measurable health benefit that would justify calling it "smarter." Noom said it disagreed with the conclusion but would voluntarily comply^[1].

What Noom's Microdose program is

Noom's Microdose GLP-1Rx Program pairs compounded semaglutide at doses of 0.2 mg to 0.6 mg per week with Noom's behaviour-change coaching app. The company markets the program as starting at $119 per month, medication included. The doses are well below the maintenance doses used in the FDA-approved labels for Ozempic (up to 2.0 mg weekly) or Wegovy (2.4 mg weekly), which is the basis for the "smaller dose" framing.

The program is a telehealth offering: a licensed clinician prescribes compounded semaglutide, and Noom provides the coaching and follow-up remotely. It is distinct from Noom's other GLP-1 programs, which offer brand-name medications at higher doses and higher price points.

What the NAD actually decided

NAD examined whether "A Smaller Dose. A Smarter Start" was puffery (a subjective, non-measurable claim that does not require substantiation) or an objective health claim that does. The division concluded that linking "smarter" to "smaller dose" conveys a measurable health benefit, specifically that using a lower dose of GLP-1 medication is a better way to begin treatment. That kind of claim requires evidence^[1].

Noom did not produce evidence sufficient to support that message. NAD recommended that the company either drop the claim entirely or modify its advertising so it no longer ties the "smarter start" framing to dosage-related health benefits^[1].

NAD was careful to note that Noom can still promote its behaviour-change tools as a "smarter start" on their own. The restriction applies only when that message is tied to unsupported claims about the dose of medication itself^[1].

Claims Noom dropped during the process

During the inquiry, Noom permanently discontinued all other challenged claims without waiting for NAD to review them. These included claims about dosing, efficacy, side effects, and other health outcomes^[1]. The decision to withdraw those claims voluntarily suggests Noom recognised they would not survive scrutiny.

Why Eli Lilly cares

Eli Lilly sells tirzepatide as both Mounjaro (for type 2 diabetes) and Zepbound (for weight management). Both are FDA-approved at specific dose escalation schedules based on Phase 3 trial data. When a competitor suggests that a "smaller dose" of a GLP-1 is a "smarter" way to start, it implicitly questions whether the dosing schedules in the approved labels are the right approach. For a company whose products are defined by those schedules, that message is a direct competitive concern.

Eli Lilly has filed several other NAD challenges against companies marketing compounded GLP-1 products in 2025 and 2026. Novo Nordisk, which makes semaglutide (Ozempic, Wegovy, Rybelsus), has done the same. The pattern is consistent: brand-name manufacturers are using NAD as a tool to police advertising claims in the compounded GLP-1 space.

The bigger picture for GLP-1 advertising

This case lands in the middle of a much larger regulatory effort. In September 2025, the FDA sent more than 55 warning letters to online sellers of compounded GLP-1 medications for misleading claims. In February 2026, the FDA issued another 30 warning letters to telehealth companies, citing "sameness" claims that suggested compounded products were equivalent to FDA-approved versions^[2].

The NAD has reviewed multiple cases in the same period. In December 2025, it recommended Willow Health Services modify or drop claims about its compounded semaglutide tablets after Novo Nordisk filed a challenge. Several other companies (Regen Doctors, Striker Pharmacy, Begin Anew MedSpa, among others) voluntarily dropped their challenged claims before NAD completed its review^[3].

The Noom case is notable because Noom is not a compounding pharmacy or a small telehealth startup. It is a well-known consumer health brand with significant venture funding and mainstream visibility. When NAD recommends that Noom change its advertising, the signal reaches further than a warning to a pharmacy most consumers have never heard of.

What this does not settle

NAD's decision does not address whether microdosing GLP-1 medications works or does not work for weight loss. It does not address whether compounded semaglutide is safe. It does not evaluate the clinical merits of starting at lower doses and titrating up slowly. Those are questions for clinical trials and regulators, not for an advertising self-regulatory body.

What NAD decided is narrower: that Noom's specific advertising claim linked a lower dose to a health benefit without supporting evidence, and that the claim should change. Noom agreed. Whether the underlying approach has merit is a separate question that the current evidence base does not answer clearly.

This article is for educational and journalistic purposes only and does not constitute medical advice. If you are considering a GLP-1 medication, whether brand-name or compounded, consult a qualified healthcare professional.